LncRNA ZFAS1 serves as a prognostic biomarker to predict the survival of patients with ovarian cancer.

LncRNA ZFAS1 serves as a prognostic biomarker to predict the survival of patients with ovarian cancer. Exp Ther Med. 2019 Dec;18(6):4673-4681 Authors: Han S, Li DZ, Xiao MF Abstract Ovarian cancer (OC) is one of the most fatal types of gynecological malignancy. Certain long non-coding RNAs (lncRNA) have been reported to have crucial roles in cancer progression. Zinc finger nuclear transcription factor, X-box binding 1-type containing 1 antisense RNA 1 (ZFAS1) is a novel regulator lncRNA in various cancer types. The expression pattern of most lncRNAs, including ZFAS1, in OC remains to be determined. In the present study, it was demonstrated that ZFAS1 was overexpressed in OC vs. normal cell lines. However, ZFAS1 was downregulated in OC compared with normal samples in the GEPIA dataset. Furthermore, OC samples of higher stages (stage III/IV) had higher levels of ZFAS1 compared with those in early-stage OC (stage I/II) samples. Of note, higher ZFAS1 expression was associated with shorter overall survival time and disease-free survival time of OC patients. Protein-protein interaction networks of proteins co-expressed with ZFAS1 in OC were constructed. Furthermore, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis of genes co-expressed with ZFAS1 indicated that ZFAS1 is associated with translation, mRNA splicing, cell-cell adhesion, DNA repair, protein sumoylation, positive regulation of GTPase activity and DNA replication. The present study m...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research

Related Links:

ConclusionsClosure of VVF is a significant challenge, with an initial success rate of 20% and an overall success rate of only 25%. Seventy percent required primary or secondary urinary diversion. Vaginal surgery was utilised in the majority to try to avoid a hostile pelvis, but the surgical approach should be tailored to individual circumstances.
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Ovarian cancer (OC) accounts for more than 150,000 deaths worldwide every year. Patients are often diagnosed at an advanced stage with metastatic dissemination. Although platinum- and taxane-based chemotherapies are effective treatment options, they are rarely curative and eventually, the disease will progress due to acquired resistance. Emerging evidence suggests a crucial role of long non-coding RNAs (lncRNAs) in the response to therapy in OC. Transcriptome profiling studies using high throughput approaches have identified differential expression patterns of lncRNAs associated with disease recurrence. Furthermore, severa...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 January 2020Source: Best Practice &Research Clinical Obstetrics &GynaecologyAuthor(s): Noa Amin, Narda Chaabouni, Angela GeorgeAbstractAs the treatment of epithelial ovarian cancer moves further into personalised medicine, the importance of determining the presence or absence of inherited mutations in cancer susceptibility genes has grown. It is now becoming routine to test for germline mutations in the BRCA1 and BRCA2 genes, which are responsible for a significant proportion of hereditary epithelial ovarian cancer and are established predictive biomarkers of potential benefit ...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - Category: OBGYN Source Type: research
Publication date: March 2020Source: Biomedicine &Pharmacotherapy, Volume 123Author(s): Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei FangAbstractOvarian cancer is the most lethal gynecologic malignancy and the fifth most lethal cancer type overall in women. Ovarian cancer often presents genome instability, with almost half of the ovarian cancers harbor defects in one or more of the six DNA repair pathways, most of them in homologous recombination (HR). Targeting DNA repair genes has becoming a unique strategy to combat HR-deficient cancers in recent years. The multi-functional enzyme Poly ADP ri...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Our data show that MSI is present in a substantial proportion of endometrioid ovarian cancers but can also occur in other tumor subtypes. MMR deficiency/MSI typically involves the entire tumor mass, suggesting that MMR inactivation occurs early in tumorigenesis in a subset of ovarian cancers. PMID: 31924330 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Publication date: Available online 3 January 2020Source: Seminars in Cancer BiologyAuthor(s): Kelly Olino, Tristen Park, Ntia AhujaAbstractAdvances in immunotherapy, most notably antibodies targeting the inhibitory immune receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4/CD152), programmed death protein 1 (PD-1/CD279) and programmed death-ligand 1 (PD-L1/B7H1/CD274) have become effective standard therapies in advanced malignancies including melanoma,1–4 merkel cell carcinoma5, urological cancers6–8, non-small cell lung cancer9–11, mis-match repair (MMR) deficient tumors12, and Hodgkin lymphoma...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Although genetically diverse, MOC has several potential therapeutic targets. Importantly, the lack of response to platinum-based therapy observed clinically corresponds to the lack of a genomic signature associated with HRD, and MOC are thus also unlikely to respond to PARP inhibition. PMID: 31902686 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Authors: Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D Abstract In the near future, important translational questions of clinical relevance will be adressed by studies currently in progress. On the one hand, the role of PD-L1 expression must be further understood, after it was found to be relevant in the use of atezolizumab in first-line therapy of patients with metastatic triple-negative breast cancer (TNBC). No association between ef...
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
Conclusion: Our results indicate that the G allele of rs1052133 imparts protection to the population whereas variant rs25487 was not associated with ovarian cancer in population from the Jammu region, indicating that larger sample size is needed for further statistical validation. Further, association of other SNPs in these genes should also be carried out as their role cannot be ruled out.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Gastroschisis Repair | General Medicine | Genetics | Ovarian Cancer | Ovaries | Study | Zinc